We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Enhanced Platform Detects Cardiac Amyloidosis by Assessing Single Echocardiogram

By MedImaging International staff writers
Posted on 27 Apr 2023
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)
Image: The EchoGo Amyloidosis platform has received FDA breakthrough device designation (Photo courtesy of Ultromics)

Cardiac amyloidosis, a condition resulting from abnormal protein deposits in heart tissue, is a diverse disease that can be challenging to diagnose, often necessitating specialized expertise and testing. The disease is categorized based on the specific protein involved, with the primary subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by the misfolding of the transthyretin protein, and a less common form called light chain amyloidosis (AL cardiac amyloidosis), caused by the buildup of immunoglobulin light chains. Now, an AI-powered platform can detect cardiac amyloidosis by analyzing echocardiograms and using just one commonly acquired ultrasound view of the heart.

The platform, EchoGo Amyloidosis, from Ultromics (Oxford, UK) utilizes AI technology to address the unmet need for early diagnosis of amyloidosis patients, who might otherwise remain undiagnosed until the disease has progressed, delaying treatment and negatively affecting patient outcomes. Developed in collaboration with multiple leading clinical partners, EchoGo Amyloidosis is designed as a module within Ultromics' EchoGo Platform and has received FDA Breakthrough Device Status. This FDA Breakthrough Device Designation represents a significant advancement for amyloidosis patients, who face a bleak five-year mortality rate of 44%-65% after diagnosis if the condition is not detected early enough.

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients."

Related Links:
Ultromics 

Portable X-ray Unit
AJEX140H
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Ultrasound Table
Women’s Ultrasound EA Table
High-Precision QA Tool
DEXA Phantom

Channels

General/Advanced Imaging

view channel
Image: Example snapshots of the photon energy density at t = 0.5, 0.7, 0.9, 1.1 nanoseconds (ns) on the y = 2.0 cm plane (Horie, S., Yajima, H., Abe, M. et al., Biomedical Engineering Letters (2026). DOI: 10.1007/s13534-026-00578-9)

AI Tool Enables Real-Time Diffuse Optical Tomography for Brain Lesion Detection

Diffuse optical tomography is a noninvasive imaging technique that uses near-infrared light to detect internal abnormalities such as cerebral hemorrhage and tumors. Its clinical utility for real-time ... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.